High Margin Biofuels And $25M Facility Will Face US Risks

Published
16 Apr 25
Updated
18 Jun 25
AnalystConsensusTarget's Fair Value
US$19.67
98.3% undervalued intrinsic discount
18 Jun
US$0.34
Loading
1Y
-94.9%
7D
-13.3%

Author's Valuation

US$19.7

98.3% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on01 May 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on24 Apr 25
Fair value Decreased 21%

AnalystConsensusTarget has increased revenue growth from -30.8% to -21.1% and decreased future PE multiple from 27.0x to 24.2x.